Acyclovir News and Research

RSS
Acyclovir is a synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses. After conversion in vivo to the active metabolite acyclovir triphosphate, acyclovir competitively inhibits viral DNA polymerase, incorporates into and terminates the growing viral DNA chain, and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the thymidine kinase of HSV.
Shingles raises the risk for heart attack and stroke

Shingles raises the risk for heart attack and stroke

Slayback Pharma launches Generic Zovirax Ointment 5% for herpes virus infections

Slayback Pharma launches Generic Zovirax Ointment 5% for herpes virus infections

Study compares medications for treatment of persons with recurrent genital herpes

Study compares medications for treatment of persons with recurrent genital herpes

Ethosomes may be effective carrier system for transdermal delivery

Ethosomes may be effective carrier system for transdermal delivery

Luminex receives rapid clearance from FDA for ARIES System and ARIES HSV 1&2 Assay

Luminex receives rapid clearance from FDA for ARIES System and ARIES HSV 1&2 Assay

Vaginal silicone ring may protect women against HIV, herpes virus

Vaginal silicone ring may protect women against HIV, herpes virus

NanoViricides speeds up HerpeCide drug development program

NanoViricides speeds up HerpeCide drug development program

NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

Common herpes drug Valacyclovir decreases HIV-1 levels

Common herpes drug Valacyclovir decreases HIV-1 levels

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

SLU investigators find promising candidates for new herpes virus treatments

SLU investigators find promising candidates for new herpes virus treatments

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

BioAlliance Pharma, Daewoong sign new licensing agreement for commercialization of Sitavig in South Korea

BioAlliance Pharma, Daewoong sign new licensing agreement for commercialization of Sitavig in South Korea

Risk factors linked to death may be reversible in severe encephalitis patients

Risk factors linked to death may be reversible in severe encephalitis patients

EADV spring symposium: Bioalliance Pharma presents Sitavig study results

EADV spring symposium: Bioalliance Pharma presents Sitavig study results

JPIDS releases consensus statement of Sentinel Project on Pediatric Drug-Resistant Tuberculosis

JPIDS releases consensus statement of Sentinel Project on Pediatric Drug-Resistant Tuberculosis

FDA approves Mylan's ANDA for generic version of Zovirax Ointment

FDA approves Mylan's ANDA for generic version of Zovirax Ointment

A new strategy to prevent herpes virus infections

A new strategy to prevent herpes virus infections

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer